Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 18/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13853640 | 0.87 | ACHE (0.75) | ACHE | |
| SCHEMBL3886212 | 0.84 | ACHE (0.71) | ACHE | |
| SCHEMBL13853634 | 0.84 | ACHE (0.70) | ACHE | |
| SCHEMBL13853633 | 0.82 | ACHE (0.67) | ACHE | |
| SCHEMBL10607673 | 0.79 | ACHE (0.63) | ACHE | |
| SCHEMBL14374375 | 0.79 | ACHE (0.76) | ACHE | |
| SCHEMBL13853639 | 0.79 | ACHE (0.63) | ACHE | |
| SCHEMBL13853641 | 0.78 | ACHE (0.62) | ACHE | |
| SCHEMBL14242602 | 0.76 | ACHE (0.60) | ACHE | |
| SCHEMBL13131169 | 0.75 | ACHE (0.59) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131535-A1 | PROPARGYLAMINO INDAN DERIVATIVES AND PROPARGYLAMINO TETRALIN DERIVATIVES AS BRAIN-SELECTIVE MAO INHIBITORS | TEVA PHARMACEUTICALS INDUSTRIES, LTD. | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131535-A1 | PROPARGYLAMINO INDAN DERIVATIVES AND PROPARGYLAMINO TETRALIN DERIVATIVES AS BRAIN-SELECTIVE MAO INHIBITORS | MAOA, MAOB, AOC3 | ACHE 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.